Stockscreener 앱 받기
1.08
0.00%
0.00
시간 외 거래:
1.08
전일 마감가:
$1.08
열려 있는:
$1.0949
하루 거래량:
33,325
Relative Volume:
0.16
시가총액:
$32.59M
수익:
-
순이익/손실:
$-60.70M
주가수익비율:
-0.5294
EPS:
-2.04
순현금흐름:
$-61.05M
1주 성능:
+1.89%
1개월 성능:
+1.89%
6개월 성능:
+0.00%
1년 성능:
-59.09%
1일 변동 폭
$1.0705
$1.10
1주일 범위
$1.03
$1.10
52주 변동 폭
$0.87
$1.675
An 2 Therapeutics Inc Stock (ANTX) Company Profile
명칭
An 2 Therapeutics Inc
전화
(650) 331-9090
주소
1800 EL CAMINO REAL, SUITE D, MENLO PARK
ANTX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ANTX
An 2 Therapeutics Inc
|
1.08 | 32.44M | 0 | -60.70M | -61.05M | -2.04 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
An 2 Therapeutics Inc Stock (ANTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-08-09 | 다운그레이드 | Evercore ISI | In-line → Underperform |
| 2024-08-09 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2024-07-03 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-04-02 | 업그레이드 | JMP Securities | Mkt Perform → Mkt Outperform |
| 2024-02-13 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2024-02-12 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2024-02-12 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2024-02-12 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2024-01-04 | 개시 | JMP Securities | Mkt Outperform |
| 2022-07-18 | 재개 | Oppenheimer | Outperform |
모두보기
An 2 Therapeutics Inc 주식(ANTX)의 최신 뉴스
Tenaya Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update - Yahoo Finance
Windtree Therapeutics, Inc. Reports Positive Interim Analysis for Istaroxime in Phase 2 Study of Cardiogenic Shock - Quiver Quantitative
BioXcel Therapeutics Completes Phase 3 Trial, Awaits FDA Decision - StocksToTrade
Apogee Therapeutics, Inc. (APGE) Soars on Promising Phase 2 Results for Atopic Dermatitis Drug - MSN
BioXcel Therapeutics Announces Last Patient Last Visit in SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia - GlobeNewswire
Cardiol Therapeutics Announces Database Lock for Phase II ARCHER Trial of CardiolRx(TM) in Acute Myocarditis - Newsfile
Cognition Therapeutics, Inc. Reports Promising Results for Zervimesine in Phase 2 Alzheimer’s and Dementia with Lewy Bodies Studies - Nasdaq
Cognition Therapeutics' Positive Clinical Data from Zervimesine (CT1812) Phase 2 Study in Dementia with Lewy Bodies (DLB) will be Presented in a Podium Presentation at AAIC - GlobeNewswire
Compass Therapeutics And 2 Other Promising Penny Stocks To Watch - Yahoo Finance
Ovid Therapeutics (NASDAQ:OVID) Stock Price Down 2% – Time to Sell? - Defense World
Cognition Therapeutics, Inc. Discusses Phase 2 Results and Future Plans for Zervimesine Treatment in Alzheimer's Disease with FDA - Nasdaq
Cognition Therapeutics Completes End-of-Phase 2 Meeting with FDA for Zervimesine (CT1812) in Alzheimer’s Disease - GlobeNewswire
Breakthrough for Alzheimer's Treatment: FDA Meeting Clears Path for Zervimesine Phase 3 Program - Stock Titan
Unicycive Therapeutics (NASDAQ:UNCY) Trading 2% Higher – Time to Buy? - Defense World
Avenzo Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Study of AVZO-1418, a Potential Best-in-Class EGFR/HER3 Bispecific Antibody-Drug Conjugate - Business Wire
Apogee Therapeutics Announces Positive 16-Week Data from - GlobeNewswire
New Atopic Dermatitis Drug Shows Record-Breaking 67% Success Rate, Could Reduce Injections to Just 4 Times Per Year - Stock Titan
Apogee Therapeutics to Host Conference Call to Report Part A 16-Week Data from the Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis on July 7, 2025 - GlobeNewswire
Cognition Therapeutics Shares Jump 12% After Hours Following Encouraging Phase 2 Alzheimer's Trial Data - Benzinga
Alembic Pharmaceuticals up 2% as arm acquires Utility Therapeutics; details - Business Standard
Pelthos Therapeutics Completes Merger with Channel Therapeutics and Closes $50.1 Million Private Placement - GlobeNewswire
Cognition Therapeutics Reports Over 50% Enrollment in Phase 2 START Study for Alzheimer's Treatment - Nasdaq
Arcturus Therapeutics Announces Positive Interim Phase 2 Multiple Dose Data for Ornithine Transcarbamylase (OTC) Deficiency Program - Yahoo Finance
Allarity Therapeutics Announces Dosing of Second Patient in - GlobeNewswire
Cognition Therapeutics Provides Regulatory Update on Zervimesine (CT1812) in Alzheimer’s Disease and Dementia with Lewy Bodies (DLB) - GlobeNewswire
Sangamo Therapeutics Announces Positive Topline Results From Registrational STAAR Study in Fabry Disease - Business Wire
Arcturus Therapeutics to Host Key Opinion Leader (KOL) Presentation of ARCT-810 Phase 2 Interim Data for Ornithine Transcarbamylase (OTC) Deficiency - Yahoo Finance
Actuate Therapeutics Reports Positive Biomarker and Machine Learning Data from Phase 2 Elraglusib Trial in First-Line Treatment of Metastatic Pancreatic Cancer at ASCO - GlobeNewswire
$452M Deal: Processa's Phase 2 Gastroparesis Drug Shows Promise, Attracts Major Licensing Interest - Stock Titan
Celldex Presents Data Demonstrating Profound Long Term Improvement in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2025 - GlobeNewswire
Layoff Tracker: ADC Therapeutics Cutting 30% of Staff, Closing London Research Facility - BioSpace
BioRestorative Therapies, Inc. Reports Promising Phase 2 Clinical Trial Results for BRTX-100 at ISSCR 2025 Annual Meeting - Nasdaq
Celldex Presents Phase 2 Study In Chronic Spontaneous Urticaria At Eaaci Congress 2025 - marketscreener.com
Compass Therapeutics And 2 Other Promising Penny Stocks For Your Watchlist - Yahoo Finance
Intensity Therapeutics, Inc. Announces Pricing of Public Offering - PR Newswire
Intensity Therapeutics, Inc. Announces Proposed Public Offering of Common Stock - PR Newswire
Intensity Therapeutics, Inc. Announces Patients Receiving INT230-6 Prior to the Start of Standard-of-Care May Achieve High Levels of Tumor Necrosis in the Ongoing Randomized Controlled Phase 2 INVINCIBLE-4 Study - Morningstar
Breakthrough: New Cancer Drug INT230-6 Destroys Tumors in Just 8 DaysPhase 2 Trial Results - Stock Titan
Avenzo Therapeutics Initiates Phase 1/2 Clinical Study of AVZO-023, a Potential Best-in-Class, Novel CDK4 Selective Inhibitor - Business Wire
Avenzo Therapeutics Initiates Phase 1/2 Clinical Study of AVZO-1418, a Potential Best-in-Class, Novel EGFR/HER3 Bispecific Antibody-Drug Conjugate - Business Wire
Aclaris Therapeutics, Inc. Initiates Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis - marketscreener.com
Lyra Therapeutics Reports Positive Results From The Enlighten 2 Phase 3 Trial Of Lyr-210 - marketscreener.com
Allarity Therapeutics Announces First Patient Enrolled in - GlobeNewswire
Allarity Therapeutics Announces First Patient Enrolled in New Phase 2 Clinical Trial Protocol of Stenoparib in Advanced Ovarian Cancer - The Manila Times
Sapience Therapeutics Provides Data Update from Phase 2 Trial of Lucicebtide in Patients with Glioblastoma at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting - PR Newswire
Aclaris Therapeutics Initiates Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis - GlobeNewswire
Lyra Therapeutics Reports Positive Results from the ENLIGHTEN 2 Phase 3 Trial of LYR-210 Achieving Statistically Significant Results for Primary and Key Secondary Endpoints in the Treatment of Chronic Rhinosinusitis (CRS) - GlobeNewswire
Actuate Therapeutics Shares Highlights from KOL Event on - GlobeNewswire
Certain Stock Options of Edgewise Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 2-JUN-2025. - marketscreener.com
Taiho Oncology and Cullinan Therapeutics Announce Pivotal REZILIENT1 Phase 1/2 Data Published in the Journal of Clinical Oncology - The Malaysian Reserve
Kymera Therapeutics, Inc. (KYMR) to Announce KT-621 Phase 1 Results on June 2, 2025 - Insider Monkey
An 2 Therapeutics Inc (ANTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
3.39%
자본화:
|
볼륨(24시간):